Date: 2011-05-31
Type of information: Capital increase
Company: Tigenix (Belgium)
Investors:
Amount: € 15.2 million
Funding type: capital increase
Planned used: With this capital increase of € 15.2 million now successfully subscribed, TiGenix has been able to secure more than € 33 million to support the future growth of the company as the European cell therapy leader.
Others: TiGenix has announced that 100% of the rights issue has now been committed. The preferential rights that were not exercised during the rights offering period were offered for sale through a scrip placement procedure. All of these scrips were sold to institutional investors, amongst which some top-tier European biotech investors. These investors will irrevocably subscribe to 1 new share per 5 scrips at the subscription price of € 1.00 per share. Following the rights offering, 75,935,555 rights have been exercised and consequently 15,187,111 new shares have been subscribed. The capital increase of € 15,187,111 will take place on June 6, 2011. No proceeds will be paid to scrip holders.
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
